Insider Transactions in Q1 2024 at Avidity Biosciences, Inc. (RNA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$115,000
$23.97 P/Share
|
|
Mar 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.14%
|
$5,000
$1.24 P/Share
|
|
Mar 13
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
40,000
-47.57%
|
$960,000
$24.52 P/Share
|
|
Mar 13
2024
|
Michael F Mac Lean Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+32.23%
|
$320,000
$8.82 P/Share
|
|
Mar 12
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
27,641
-36.99%
|
$608,102
$22.02 P/Share
|
|
Mar 12
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+37.05%
|
$25,000
$1.24 P/Share
|
|
Mar 12
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
28,000
-19.98%
|
$616,000
$22.63 P/Share
|
|
Mar 12
2024
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+16.66%
|
$28,000
$1.24 P/Share
|
|
Mar 08
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
84,000
-42.83%
|
$1,764,000
$21.39 P/Share
|
|
Mar 08
2024
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
84,000
+29.99%
|
$84,000
$1.24 P/Share
|
|
Mar 01
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
84,000
-42.83%
|
$1,680,000
$20.13 P/Share
|
|
Mar 01
2024
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
84,000
+29.99%
|
$84,000
$1.24 P/Share
|
|
Jan 22
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
1,859
-9.62%
|
$18,590
$10.13 P/Share
|
|
Jan 22
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,616
-8.74%
|
$16,160
$10.13 P/Share
|
|
Jan 22
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
2,065
-10.81%
|
$20,650
$10.13 P/Share
|
|
Jan 22
2024
|
W. Michael Flanagan CSTO |
SELL
Open market or private sale
|
Direct |
4,129
-10.32%
|
$41,290
$10.13 P/Share
|
|
Jan 22
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
5,092
-10.37%
|
$50,920
$10.13 P/Share
|
|
Jan 20
2024
|
Michael F Mac Lean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+45.26%
|
-
|
|
Jan 20
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+48.59%
|
-
|
|
Jan 20
2024
|
W. Michael Flanagan CSTO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+49.64%
|
-
|
|
Jan 20
2024
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+48.18%
|
-
|